Suchergebnisse - "Shiu, Kai-Keen"

PubPharm (5)

1

Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply

enthalten in: The Lancet. Oncology | 2022

von André, T. | Diaz, L. | Shiu, K.

CommentOn: Lancet Oncol. 2022 May;23(5):659-670. - PMID 35427471

2

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

enthalten in: Cancer cell | 2021

von Au, L. | Hatipoglu, E. | Robert de Massy, M. | +155

CommentIn: Cell Rep Med. 2021 Nov 16;2(11):100445. - PMID 34841292

3

Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade : Analysis of the KEYNOTE 177 Trial and Validation Cohorts

enthalten in: Gastroenterology | 2021

von Bortolomeazzi, M. | Keddar, M. | Montorsi, L. | +26

4

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

enthalten in: The New England journal of medicine | 2020

von André, T. | Shiu, K. | Kim, T. | +119

CommentIn: N Engl J Med. 2020 Dec 3;383(23):2283-2285. - PMID 33264550

5

Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors

enthalten in: Targeted oncology | 2020

von Formica, V. | Morelli, C. | Patrikidou, A. | +8

1
[1]